Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences Inc. for $600 million in a cash-and-stock deal. Tina Nova, Decipher’s president and CEO, will join Veracyte as general manager, urologic cancers. 

First close, second fund
V-Bio Ventures announced the first close of V-Bio Fund 2 with capital commitments of €78 million ($94.3 million) to invest in early-stage European life sciences companies. The Belgian firm also said it added Shelley Margetson as managing partner...